Working capital absorbed NZ$58.7m, draining operating cash to NZ$1.9m

This drained operating cash flow by 98.5% to NZ$1.9m and turned pre-lease free cash flow to -NZ$129.6m (HY22: +NZ$39.6m). Inventory days climbed to 105 from a historical mean of 67.2, with inventories up 36.5% to NZ$398.4m.

Revenue fell 23.3% to NZ$690.6m as post-pandemic hospital hardware demand normalised — Hospital product group revenue dropped to NZ$438.7m from NZ$670.0m, while Homecare grew to NZ$249.9m. PBT fell 62.0% and NPAT fell 56.8% to NZ$95.9m, the NPAT decline partly cushioned by an effective tax rate of 16.1% (HY22: 26.3%). The interim dividend was lifted to 17.5 cents from 17.0 cents.

With inventory days at 105 versus a historical baseline of 67.2 days and the working-capital draw at NZ$58.7m (vs ~NZ$0.1m historically), cash conversion is now the principal risk. Dividend payout climbed to 105.4% of NPAT, above the 73.4% historical mean and not covered by free cash flow. The company is funding capital returns and elevated capex (NZ$124.8m, 18.1% of revenue) from balance-sheet capacity — gross borrowings rose 55.5% to NZ$112.4m and net debt swung from net cash of NZ$30.9m to net debt of NZ$42.6m.

Revenue normalisation, not contraction. Management frames the 23.3% revenue decline against an extraordinary pandemic comparator and notes a 21% increase versus pre-pandemic HY20. The mix shifted markedly, with Homecare's share moving from 25.2% to 36.2%, which matters because Homecare typically carries different margin and growth dynamics than hardware-led Hospital.

Tax tailwind flatters NPAT. The effective tax rate dropped to 16.1% from 26.3%, narrowing the NPAT decline to 56.8% versus a 62.0% PBT decline. PBT is the cleaner operating read here; readers comparing NPAT alone will understate the underlying earnings deterioration.

No FY23 target was disclosed in the supplied excerpts.

On second-half shape, HY22 represented 53.5% of FY22 revenue and 58.8% of NPAT — FY22's first half was abnormally heavy due to pandemic hardware sales, so straight annualisation of HY23 is unreliable. The release does not yet support a clear FY23 picture; the read depends on whether second-half order intake recovers from the post-pandemic destocking that drove the Hospital revenue drop. This matters because the dividend, capex programme, and net-debt trajectory are all sized to a higher run-rate than HY23 delivered.

Reported NPAT of NZ$95.9m sits against operating cash flow of NZ$1.9m and pre-lease free cash flow of -NZ$129.6m, an FCF/NPAT ratio of -135.1%. The gap is driven by inventory absorption rather than receivable stretch — debtor days actually improved to 40.5 from 40.8 — which means the working-capital pressure is a deliberate stock build, not a collection problem. Whether that inventory unwinds into second-half cash generation or becomes obsolete is the central quality question.

Earnings quality is also softened by the tax line. Stripping the tax effect, PBT contracted 62.0% versus NPAT's 56.8% decline, and ROE more than halved to 6.5% from 13.9%. Capex at 18.1% of revenue is elevated, gross borrowings rose 55.5% to NZ$112.4m, and net debt moved from net cash to NZ$42.6m of net debt. Together — uncovered dividend, balance-sheet drawdown, inventory build — these describe a half supported by balance-sheet capacity rather than current cash generation.

This briefing cannot assess gross margin trajectory or product-level pricing power, neither of which is disclosed in the supplied release.